- Home
- HYPR vs KRON Comparison
HYPR vs KRON Comparison
Compare HYPR & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- KRON
- Stock Information
- Founded
- HYPR 2014
- KRON 2017
- Country
- HYPR United States
- KRON United States
- Employees
- HYPR N/A
- KRON N/A
- Industry
- HYPR Medical Specialities
- KRON Medicinal Chemicals and Botanical Products
- Sector
- HYPR Health Care
- KRON Health Care
- Exchange
- HYPR Nasdaq
- KRON Nasdaq
- Market Cap
- HYPR 71.9M
- KRON 60.3M
- IPO Year
- HYPR N/A
- KRON 2020
- Fundamental
- Price
- HYPR $1.02
- KRON $0.90
- Analyst Decision
- HYPR Hold
- KRON Buy
- Analyst Count
- HYPR 2
- KRON 3
- Target Price
- HYPR $1.43
- KRON $1.63
- AVG Volume (30 Days)
- HYPR 126.2K
- KRON 184.6K
- Earning Date
- HYPR 11-12-2024
- KRON 11-13-2024
- Dividend Yield
- HYPR N/A
- KRON N/A
- EPS Growth
- HYPR N/A
- KRON N/A
- EPS
- HYPR N/A
- KRON N/A
- Revenue
- HYPR $13,255,000.00
- KRON $9,864,000.00
- Revenue This Year
- HYPR $31.69
- KRON $52.58
- Revenue Next Year
- HYPR $33.96
- KRON N/A
- P/E Ratio
- HYPR N/A
- KRON N/A
- Revenue Growth
- HYPR 35.67
- KRON 146.56
- 52 Week Low
- HYPR $0.76
- KRON $0.69
- 52 Week High
- HYPR $1.42
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- HYPR 59.88
- KRON 49.20
- Support Level
- HYPR $0.82
- KRON $0.84
- Resistance Level
- HYPR $0.98
- KRON $0.88
- Average True Range (ATR)
- HYPR 0.06
- KRON 0.05
- MACD
- HYPR 0.01
- KRON 0.00
- Stochastic Oscillator
- HYPR 91.45
- KRON 57.22
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its sales from the following sources: 1) device sales which consist of sales of MRI devices and 2) service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.